Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA – Get Rating)'s share price traded up 8.8% during trading on Thursday . The company traded as high as $0.75 and last traded at $0.74. 312,151 shares were traded during trading, a decline of 58% from the average session volume of 736,713 shares. The stock had previously closed at $0.68.
Analysts Set New Price Targets
A number of equities analysts have recently commented on the company. Brookline Capital Management reissued a "buy" rating on shares of Hepion Pharmaceuticals in a report on Tuesday, January 31st. Alliance Global Partners assumed coverage on Hepion Pharmaceuticals in a report on Monday, January 23rd. They set a "buy" rating for the company.
Get Hepion Pharmaceuticals alerts:Hepion Pharmaceuticals Stock Performance
The company has a market cap of $59.19 million, a price-to-earnings ratio of -1.32 and a beta of 1.64. The business has a fifty day moving average price of $0.77 and a 200 day moving average price of $0.57.
Institutional Investors Weigh In On Hepion Pharmaceuticals
A number of hedge funds and other institutional investors have recently bought and sold shares of HEPA. Renaissance Technologies LLC grew its position in Hepion Pharmaceuticals by 151.7% during the 1st quarter. Renaissance Technologies LLC now owns 126,600 shares of the company's stock worth $163,000 after acquiring an additional 76,300 shares during the last quarter. State Street Corp grew its position in Hepion Pharmaceuticals by 8.1% during the 1st quarter. State Street Corp now owns 348,910 shares of the company's stock worth $450,000 after acquiring an additional 26,194 shares during the last quarter. PVG Asset Management Corp bought a new stake in Hepion Pharmaceuticals during the 3rd quarter worth $55,000. Virtu Financial LLC grew its position in Hepion Pharmaceuticals by 195.6% during the 3rd quarter. Virtu Financial LLC now owns 67,802 shares of the company's stock worth $34,000 after acquiring an additional 44,867 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its position in Hepion Pharmaceuticals by 45.8% during the 3rd quarter. Envestnet Asset Management Inc. now owns 87,541 shares of the company's stock worth $44,000 after acquiring an additional 27,487 shares during the last quarter. Institutional investors own 9.37% of the company's stock.
About Hepion Pharmaceuticals
(Get Rating)
Hepion Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease.
Recommended Stories
- Get a free copy of the StockNews.com research report on Hepion Pharmaceuticals (HEPA)
- MarketBeat Week in Review – 3/27 – 3/31
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
Receive News & Ratings for Hepion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hepion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.